Pharmacovigilance: Serious vs Severity in Drug Safety Reporting Lakkireddy Sowmya posted on the topic LinkedIn A pharmacovigilance datadriven approach to reveal high fatal adverse events following checkpoint immunotherapy PNAS Population scale identification of differential adverse events before and during a pandemic Nature Computational Science Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab From toxicity assessment to adaptive safety care: implementing comprehensive fast track safety evaluation for anticancer drug development ESMO Open Under reporting of harm in clinical trials The Lancet Oncology